Prevalence of chloroquine and antifolate drug resistance markers in Plasmodium falciparum parasites in Rwanda, 2018

Malaria remains one of the most persistent threats to human health, particularly in sub-Saharan Africa, where the disease claims millions of lives annually. For decades, the global fight against malaria has relied on a small arsenal of medicines to kill the parasite that causes the illness. However, the parasite is a relentless adversary; it constantly evolves, developing defenses that render these drugs useless. This phenomenon, known as drug resistance, is not a sudden event but a gradual shift in the genetic makeup of the parasite population. When a drug is used heavily, it acts as a filter, killing off the vulnerable parasites while allowing those with specific genetic mutations to survive and reproduce. Over time, the entire population becomes dominated by these resistant strains, leaving doctors with no effective treatment. To stay ahead of this biological arms race, scientists must constantly monitor the genetic code of the parasites circulating in different regions, looking for the specific mutations that signal a drug is losing its power.

In 2018, researchers turned their attention to Rwanda, a country with a complex history of malaria treatment policies. For years, the nation had shifted its primary medicines in response to resistance, moving from chloroquine to a combination of amodiaquine and sulfadoxine-pyrimethamine, and finally to artemisinin-based combination therapies. Despite these changes, the threat of resistance never fully disappeared. A team of scientists from the Swiss Tropical and Public Health Institute and the Rwanda Biomedical Center set out to map the current genetic landscape of the malaria parasite in three specific locations: Masaka in the capital city, Rukara in the east, and Bugarama in the west. Their goal was to determine if the parasites had developed new defenses against the drugs currently in use, or if they were reverting to a state where older medicines might work again.

The researchers collected blood samples from patients infected with the parasite at these three sites. They extracted the genetic material from the dried blood spots and sequenced specific genes known to be responsible for drug resistance. They focused on three main genetic targets: one gene that determines resistance to chloroquine, and two others that determine resistance to sulfadoxine-pyrimethamine. By reading the genetic code, they could identify exactly which mutations were present and how widespread they were. This molecular surveillance provided a snapshot of the parasite's defenses at that specific moment in time, offering a clearer picture than clinical observations alone could provide.

The findings revealed a story of slow, uneven recovery regarding chloroquine. This drug had been banned in Rwanda for over a decade, and scientists had hoped that without the pressure of the drug, the parasites would naturally lose their resistance and return to a vulnerable state. The data confirmed this trend, but only partially. The mutation that confers resistance to chloroquine was found in only 10 percent of all the samples collected across the country. More importantly, this resistance was not evenly distributed. It appeared exclusively in the western site of Bugarama, where it affected 26 percent of the parasites. In the other two locations, Masaka and Rukara, the parasites had completely reverted to the wild type, meaning they were once again susceptible to chloroquine. This suggests that the country is slowly recovering its ability to treat malaria with older drugs, but the process is incomplete and varies significantly from one region to another.

However, the situation with other drugs was far more concerning. The researchers looked at the genes responsible for resistance to sulfadoxine-pyrimethamine, a drug that had been removed from the national treatment regimen in 2008. Despite the drug being absent from the treatment system for ten years, the genetic markers for resistance remained alarmingly high. The mutations that protect the parasite from this drug were found in nearly all the samples. Specifically, the mutations that create a "quintuple" combination of resistance were present in 84 percent of the parasites, and an even more complex "sextuple" combination was found in 50 percent. Even more troubling was the presence of a highly resistant mutation known as I164L. This specific mutation, which makes the parasite extremely difficult to kill, was found in 16 percent of the total samples, but it was concentrated in the eastern and central sites, appearing in 28 percent of samples in Rukara and 25 percent in Masaka.

The study also uncovered a fascinating interaction between the parasites and the current standard treatment, a combination of artemether and lumefantrine. The researchers noticed that the parasites carrying the new mutations for partial resistance to artemisinin were almost always the ones that had lost their resistance to chloroquine. In other words, the parasites that survived the current treatment were the ones that had returned to a wild type for the chloroquine gene. This suggests that the current drug regimen might be inadvertently selecting for these specific parasites, favoring those that are less susceptible to the lumefantrine component of the treatment. This dynamic implies that the very drugs used to treat the disease are shaping the genetic future of the parasite population in unexpected ways.

The persistence of these resistance markers, particularly the highly resistant I164L mutation, despite the absence of the drug that originally selected for them, presents a puzzle. The researchers considered several possibilities. They noted that the drug might be used illegally, but they deemed this unlikely to be the primary driver. They also considered that another common medication, cotrimoxazole, used to treat other infections, might be exerting a similar pressure, but the specific nature of the mutations did not fully align with this theory. The most plausible explanation, supported by the geographic distribution of the mutations, is that the resistant parasites are being imported from neighboring countries. The mutation was found in the eastern and central regions, which lie along major travel routes from Uganda and Tanzania, nations where this specific resistance is known to be rising. In contrast, the western site, which borders the Democratic Republic of the Congo and Burundi, showed no sign of this mutation, suggesting a different flow of parasites across the borders.

The study concludes that while Rwanda is seeing a slow and partial return to drug susceptibility for chloroquine, the landscape for other treatments remains precarious. The high prevalence of resistance markers for sulfadoxine-pyrimethamine, including the dangerous I164L mutation, indicates that these genetic defenses are deeply entrenched and likely spreading through cross-border movement. The researchers emphasize that continuous monitoring is essential. The genetic makeup of the malaria parasite is not static; it is a moving target that responds to treatment policies, drug usage, and human movement. Without vigilant surveillance, the gains made in malaria control could be quickly eroded by the silent spread of these resistant strains. The data from 2018 serves as a critical baseline, highlighting the need to watch closely as the parasite continues to evolve in response to the tools humanity uses to fight it.